

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



**SinoMab BioScience Limited**

**中國抗體製藥有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 3681)**

## **SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE**

On 2 November 2022 (after trading hours), the Company entered into the Subscription Agreements with the Subscribers, all being Independent Third Parties, whereby the Subscribers conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue an aggregate of 28,680,000 Subscription Shares at the Subscription Price of HK\$1.78 each.

The Subscription Shares represent (i) approximately 2.85% of the issued share capital of the Company as at the date of this announcement; and (ii) approximately 2.78% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares (assuming there will be no change in the total number of issued Shares of the Company between the date of this announcement and the allotment and issue of the Subscription Shares.) As the Subscription Shares will be allotted and issued pursuant to the General Mandate, the Subscription Agreements and the transactions contemplated thereunder are not subject to the approval of the Shareholders.

The Subscription Price was arrived at an arm's length negotiations between the Company and each of the Subscribers with reference to the recent trading performance of the Shares, the business prospects and financial position of the Group and the current market conditions. The Subscription Price of HK\$1.78 per Subscription Share represents (i) the closing price per Share of HK\$1.78 as quoted on the Stock Exchange on 2 November 2022, being the date of the Subscription Agreements; and (ii) a discount of approximately 0.56% to the average closing price per Share of HK\$1.79 as quoted on the Stock Exchange for the last five consecutive trading days immediately preceding the date of the Subscription Agreements.

The Company will apply to the Listing Committee for the listing of, and permission to deal in the Subscription Shares on the Stock Exchange.

Upon Completion, the aggregate gross proceeds of the Subscriptions will amount to HK\$51,050,400 and the aggregate net proceeds, after the deduction of all relevant fees and expenses, will be approximately HK\$50,890,400, representing a net Subscription Price of approximately HK\$1.77 per Subscription Share. The Company intends to utilise the net proceeds from the Subscriptions in the manner set out in the paragraph headed “REASONS FOR THE SUBSCRIPTIONS AND USE OF PROCEEDS” of this announcement.

**Shareholders and potential investors should note that completion of each of the Subscriptions is subject to fulfillment of the conditions under the relevant Subscription Agreement. As the Subscriptions may or may not proceed, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.**

## SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE

On 2 November 2022 (after trading hours), the Company entered into two (2) Subscription Agreements with two (2) Subscribers, pursuant to which the Company has conditionally agreed to allot and issue and the Subscribers have conditionally agreed to subscribe for an aggregate of 28,680,000 new Shares at the Subscription Price of HK\$1.78 per Subscription Share.

The terms of each of the Subscription Agreements are identical except for the name and details of the Subscribers.

## THE SUBSCRIPTION AGREEMENTS

The principal terms of the Subscription Agreements are set out below.

Date: 2 November 2022 (after trading hours)

Parties, number of Subscription Shares and aggregate Subscription Price:

Subscription Agreement	Parties	Number of Subscription Shares	Aggregate Subscription Price (HK\$)
A	(1) Company (2) Subscriber A	14,340,000	25,525,200
B	(1) Company (2) Subscriber B	14,340,000	25,525,200
	<b>Total</b>	<u>28,680,000</u>	<u>51,050,400</u>

## **The Subscription Shares**

The Subscription Shares in aggregate represent (i) approximately 2.85% of the issued share capital of the Company as at the date of this announcement; and (ii) approximately 2.78% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares (assuming there will be no change in the total number of issued Shares of the Company between the date of this announcement and the allotment and issue of the Subscription Shares.)

## **The Subscription Price**

The Subscription Price is fixed at HK\$1.78 per Subscription Share, which represents:

- (i) the closing price per Share of HK\$1.78 as quoted on the Stock Exchange on 2 November 2022, being the date of the Subscription Agreements;
- (ii) a discount of approximately 0.56% to the average closing price per Share of HK\$1.79 as quoted on the Stock Exchange for the last five consecutive trading days immediately preceding the date of the Subscription Agreements; and
- (iii) a discount of approximately 1.11% to the average closing price per Share of HK\$1.80 as quoted on the Stock Exchange for the last ten consecutive trading days immediately preceding the date of the Subscription Agreements.

The net Subscription Price, after deduction of all relevant fees and expenses, is estimated to be approximately HK\$50,890,400.

The Subscription Price was arrived at an arm's length negotiations between the Company and each of the Subscribers with reference to the recent trading performance of the Shares, the business prospects and financial position of the Group and the current market conditions.

The Directors (including the independent non-executive Directors) consider that the terms of the Subscription Agreements are fair and reasonable and are in the best interests of the Company and the Shareholders as a whole.

## **Condition precedent to the Completion of Subscription Agreements**

Completion of each Subscription Agreement is conditional upon the fulfillment of the condition precedent, namely upon the approval of the listing of, and permission to deal in, all the Subscription Shares being granted by the Listing Committee of the Stock Exchange (either unconditionally or subject to conditions which are acceptable to the Company).

The above-mentioned condition is not waivable by any Party. In the event that the said condition is not fulfilled by 5:00 p.m. (Hong Kong time) on 30 December 2022 (or such later time and/or date as may be agreed by the Parties in writing), all rights, obligations and liabilities of the Parties shall cease and determine and neither of the Parties shall have any claim against the other save for any antecedent breach.

## **Completion of the Subscriptions**

Subject to the fulfillment of the condition precedent in the Subscription Agreements, Completion of each Subscription Agreement will take place on the fifth (5th) Business Day after the date of fulfillment of the above condition or such other date as may be agreed amongst the Parties.

Completion of the Subscriptions are subject to fulfilment of the condition precedent in the Subscription Agreements and the Subscriptions may or not may proceed. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

## **Ranking of the Subscription Shares**

The Subscription Shares, when allotted and issued, will rank *pari passu* in all respects with the existing Shares in issue at the date of allotment and issue of the Subscription Shares.

## **General Mandate**

The Subscription Shares will be allotted and issued under the General Mandate granted to the Directors at the AGM, pursuant to which the Directors are authorised to allot and issue up to 201,248,080 Shares, being 20% of the number of issued Shares as at the date of the 2022 AGM, which was 1,006,240,400 Shares.

As at the date of this announcement, no Shares have been allotted and issued under the General Mandate. The General Mandate is sufficient for the allotment and issue of the Subscription Shares. As such, the allotment and issue of the Subscription Shares is not subject to the Shareholders' approval at a general meeting of the Company.

## **Application for listing**

Application will be made by the Company to the Stock Exchange for the listing of, and permission to deal in, the Subscription Shares.

## **INFORMATION ON THE COMPANY AND THE SUBSCRIBERS**

The Company is a company incorporated in Hong Kong with limited liability. The Group is principally engaged in research and development of pharmaceutical products.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of Subscriber A, Mr. Shanchun WANG (王善春先生) and Subscriber B, Ms. Shun Kuen CHAN (陳舜娟女士) is an Independent Third Party.

## REASONS FOR THE SUBSCRIPTIONS AND USE OF PROCEEDS

The Directors consider that the Subscriptions represent a good opportunity for the Company to raise capital to meet the Company's funding needs and strengthen the shareholding base of the Company. The Board is of the view that the terms of the Subscription Agreements and the transactions contemplated thereunder are on normal commercial terms agreed upon after arm's length negotiations between the parties, fair and reasonable and in the interests of the Company and the Shareholders as a whole.

Upon Completion, the aggregate gross proceeds of the Subscriptions will amount to HK\$51,050,400 and the aggregate net proceeds, after the deduction of all relevant fees and expenses, will be approximately HK\$50,890,400, representing a net Subscription Price of approximately HK\$1.77 per Subscription Share.

The Company intends to use the net proceeds to (i) further advance the Company's R&D programmes, expand its R&D team, build its commercialisation team, develop its proprietary technology and enhance its full-spectrum platform; and (ii) for general working capital purpose.

## FUND RAISING ACTIVITIES OF THE COMPANY IN THE PAST 12 MONTHS

The Company has not conducted any equity fund raising activity within the 12-month period prior to the date of this announcement.

## EFFECT ON SHAREHOLDING STRUCTURE

As at the date of this announcement, the Company has 1,006,240,400 Shares in issue. Assuming there will be no further changes in the issued share capital of the Company between the date of this announcement and immediately prior to the allotment and issue of the Subscription Shares in full, the shareholding structure of the Company (i) as at the date of this announcement and (ii) immediately after Completion of the Subscriptions, are set out as below for illustration purposes only:

Name of Shareholders	As at the date of this announcement		Immediately after Completion of Subscriptions	
	No. of Shares	Appropriate %	No. of Shares	Appropriate %
Mr. Jing QIANG <sup>1</sup>	72,823,636	7.24	72,823,636	7.04
Apricot Entities <sup>2</sup>	212,879,400	21.16	212,879,400	20.57
Hainan Haiyao Co., Ltd. (海南海藥股份有限公司) <sup>3</sup>	158,882,115	15.79	158,882,115	15.35
Skytech Technology Limited <sup>4</sup>	129,729,200	12.89	129,729,200	12.54
<b>Public Shareholders</b>				
Subscriber A	—	—	14,340,000	1.39
Subscriber B	—	—	14,340,000	1.39
Other Public Shareholders	<u>431,926,049</u>	<u>42.92</u>	<u>431,926,049</u>	<u>41.74</u>
Total	<u>1,006,240,400</u>	<u>100.00</u>	<u>1,034,920,400</u>	<u>100.00</u>

*Notes:*

1. 46,711,640 Shares of which were held through his wholly owned company, Grogene Technology Limited (格擎生物科技有限公司). Mr. Jing QIANG is the spouse of Ms. Wenyi LIU, a non-executive Director.
2. Shares held by Apricot Capital (上海杏澤投資管理有限公司) and Shanghai Yueyi Investment Centre (Limited Partnership)\* (上海月溢投資中心(有限合夥)) are through Apricot Oversea Holdings Limited, West Biolake Holdings Limited, Apricot BioScience Holdings, L.P., Le Rong Limited and Zliverland Holdings Limited (collectively, the “**Apricot Entities**”), which are ultimately controlled by Ms. Wenyi LIU, a non-executive Director. Ms. Wenyi LIU is the spouse of Mr. Jing QIANG.
3. Pursuant to a share charge where Hainan Haiyao Co., Ltd (海南海藥股份有限公司) (“**Hainan Haiyao**”) charged 158,882,115 Shares to China Citic Bank Co., Ltd., Haikou Branch (“**China Citic Bank**”), China Citic Bank had a security interest in 158,882,115 Shares which were beneficially owned by Hainan Haiyao.
4. Skytech Technology Limited is a company wholly owned by Dr. Shui On LEUNG, an executive Director and the chairman of the Company.

## **DEFINITIONS**

In this announcement, the following expressions shall, unless the context requires otherwise, have the following meanings:

“AGM”	the annual general meeting of the Company held on 13 June 2022 in which the Shareholders had approved, among other matters, the grant of the General Mandate
“Board”	the board of Directors
“Company”	SinoMab BioScience Limited (中國抗體製藥有限公司), a company incorporated in Hong Kong with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange
“Completion”	completion of the Subscriptions in accordance with the terms of the Subscription Agreements
“connected person(s)”	has the meaning as ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“General Mandate”	the general mandate of the Company granted to the Directors by way of passing an ordinary resolution at the AGM to, inter alia, allot, issue and deal with new Shares not exceeding 20% of the aggregate number of the issued Shares as at the date of the AGM, pursuant to which a maximum of 201,248,080 Shares may fall to be allotted and issued as at the date of this announcement
“Group”	collectively, the Company and its subsidiaries from time to time

“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Independent Third Party(ies)”	an individual or a company which is not a connected person of the Company within the meaning of the Listing Rules
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Parties” or “Party”	the named parties to the Subscription Agreements or any of them
“PRC”	the People’s Republic of China, for the purpose of this announcement excluding Hong Kong, Macau Special Administrative Region and Taiwan
“Share(s)”	ordinary share(s) in the share capital of the Company
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscriber A”	Mr. WANG Shanchun (王善春先生), an Independent Third Party
“Subscriber B”	Ms. CHAN Shun Kuen (陳舜娟女士), an Independent Third Party
“Subscribers”	collectively, the Subscribers, and “Subscriber” means any one of them
“Subscription(s)”	subscription(s) of Subscription Shares by the Subscribers at the Subscription Price pursuant to the Subscription Agreements
“Subscription Agreement A”	the subscription agreement dated 2 November 2022 entered into between the Company and Subscriber A in relation to subscription of 14,340,000 Subscription Shares
“Subscription Agreement B”	the subscription agreement dated 2 November 2022 entered into between the Company and Subscriber B in relation to subscription of 14,340,000 Subscription Shares
“Subscription Agreements”	collectively, the Subscription Agreements, and “Subscription Agreement” means any one of them
“Subscription Price”	the subscription price of HK\$1.78 per Subscription Share

“Subscription Shares” a total of 28,680,000 new Shares to be allotted and issued by the Company to the Subscribers under the Subscription Agreements

“substantial shareholder(s)” has the meaning as ascribed to it under the Listing Rules

“%” per cent.

By Order of the Board  
**SinoMab BioScience Limited**  
**Dr. Shui On LEUNG**  
*Executive Director, Chairman and Chief Executive Officer*

Hong Kong SAR, 2 November 2022

*As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.*